TheraRadar
Data updated: May 26, 2026

UNIVASC (moexipril hydrochloride)

Cardiovascular Approved 1995-04-19
1
Indication
--
Phase 3 Trials
31
Years on Market

Details

Status
Discontinued
First Approved
1995-04-19
Routes
ORAL
Dosage Forms
TABLET

Companies

Active Ingredient: MOEXIPRIL HYDROCHLORIDE

UNIVASC Approval History

1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
48 FDA actions from 1995 to 2012
Sep 2012 SUPPL
Label · Labeling
Jan 2012 SUPPL
Label · Labeling
Aug 2011 SUPPL
Label · Labeling

What UNIVASC Treats

1 FDA approvals

Originally approved for its first indication in 1995 .

  • Other (1)
📋

Clinical Trial Registry

1 trials
Trial Sponsor ID Phase Status Title
NCT07547878 RAPID-CKD 026-271 Ph 4 not yet recruiting Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

UNIVASC FDA Label Details

Track UNIVASC with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.